CTKB Q3 2021 Earnings — Cytek Biosciences, Inc. Revenue & Financial Results | Market Cap Arena

CTKBCytek Biosciences, Inc.

$523M

Q3 2021 Earnings

Healthcare Medical - Devices

Income Statement

Revenue

$34M+37.0% YoY

Gross Profit

$21M61.9% margin

Operating Income

$3M8.4% margin

Net Income

$1M4.1% margin

EPS (Diluted)

$0.01

QoQ Revenue Growth

+13.0%

Cash Flow

Operating Cash Flow

$1M

Free Cash Flow

-$147,000

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$454M

Total Liabilities

$51M

Stockholders' Equity

$403M

Cash & Equivalents

$377M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$34M	$25M	+37.0%
Gross Profit	$21M	$16M	+36.3%
Operating Income	$3M	$7M	-56.8%
Net Income	$1M	$7M	-78.3%

Revenue Segments

Product

$32M94%

Service

$2M6%

Geographic Segments

UNITED STATES

$24M70%

EMEA

$6M18%

Asia Pacific

$3M8%

Other

$1M4%